The University of Chicago Header Logo

Connection

Karen Kaul to Recombinant Fusion Proteins

Back to Details
This is a "connection" page, showing publications Karen Kaul has written about Recombinant Fusion Proteins.
Karen Kaul
Connection Strength
0.024
Recombinant Fusion Proteins
  1. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk Lymphoma. 1993 Nov; 11(5-6):369-77.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.